JNJ4796 |
カタログ番号GC65968 |
JNJ4796 は、ヘマグルチニン (HA) を介した融合を阻害することにより、インフルエンザ A グループ 1 ウイルスを中和する、インフルエンザ ウイルスの経口活性融合阻害剤です。 JNJ4796 は、広域中和抗体 (bnAbs) の機能を模倣しています。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2241664-16-2
Sample solution is provided at 25 µL, 10mM.
JNJ4796 is an oral active fusion inhibitor of influenza virus, neutralizing influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 mimics the functionality of the broadly neutralizing antibodies (bnAbs)[1].
Like bnAb CR6261, the mechanism of action of JNJ4796 is demonstrated to be based on inhibition of the pH-sensitive conformational change of HA that triggers fusion of the viral and endosomal membranes and release of the viral genome into the host cell[1].
Oral administration of JNJ4796 protects mice from lethal challenge of 25 times the median lethal dose (LD50) of H1N1 A/Puerto Rico/8/1934 virus. Doses of 50 and 10 mg/kg of JNJ4796 twice daily, initiated one day before challenge and continuing for 7 days, results in 100% survival at day 21 in comparison to the less potent compound JNJ8897 for which less than 50% survival is achieved[1].
Oral doses of JNJ4796 results in dose-dependent efficacy after a sublethal viral challenge (LD90), with twice daily administration of 15 and 5 mg/kg of JNJ4796 giving rise to 100% survival[1].
Animal Model: | Female BALB/cAnNCrl mice intranasally infected with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34 dissolved in sterile phosphate buffered saline (D-PBS)[1] |
Dosage: | 50 and 10 mg/kg. |
Administration: | Oral twice daily for 7 days. |
Result: | Resulted in 100% survival at day 21 in comparison to the less potent compound JNJ8897. |
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *